22 results on '"Bruni, Alessio"'
Search Results
2. Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting
- Author
-
Francolini, Giulio, Stocchi, Giulia, Detti, Beatrice, Di Cataldo, Vanessa, Bruni, Alessio, Triggiani, Luca, Guerini, Andrea Emanuele, Mazzola, Rosario, Cuccia, Francesco, Mariotti, Matteo, Salvestrini, Viola, Garlatti, Pietro, Borghesi, Simona, Ingrosso, Gianluca, Bellavita, Rita, Aristei, Cynthia, Desideri, Isacco, and Livi, Lorenzo
- Published
- 2022
- Full Text
- View/download PDF
3. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis
- Author
-
Valeriani, Maurizio, Detti, Beatrice, Fodor, Andrei, Caini, Saverio, Borghesi, Simona, Trippa, Fabio, Triggiani, Luca, Bruni, Alessio, Russo, Donatella, Saldi, Simonetta, Di Staso, Mario, Francolini, Giulio, Lancia, Andrea, Marinelli, Luca, Di Muzio, Nadia, Aristei, Cynthia, Livi, Lorenzo, Magrini, Stefano Maria, and Ingrosso, Gianluca
- Published
- 2022
- Full Text
- View/download PDF
4. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
- Author
-
Triggiani, Luca, Mazzola, Rosario, Magrini, Stefano Maria, Ingrosso, Gianluca, Borghetti, Paolo, Trippa, Fabio, Lancia, Andrea, Detti, Beatrice, Francolini, Giulio, Matrone, Fabio, Bortolus, Roberto, Fanetti, Giuseppe, Maranzano, Ernesto, Pasqualetti, Francesco, Paiar, Fabiola, Bonù, Marco Lorenzo, Magli, Alessandro, Bruni, Alessio, Mazzeo, Ercole, Franzese, Ciro, Scorsetti, Marta, Alongi, Filippo, Jereczek-Fossa, Barbara Alicja, Ost, Piet, and Buglione, Michela
- Published
- 2019
- Full Text
- View/download PDF
5. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group
- Author
-
Borghetti, Paolo, Bonù, Marco Lorenzo, Giubbolini, Rachele, Levra, Niccolo’ Giaj, Mazzola, Rosario, Perna, Marco, Visani, Luca, Meacci, Fiammetta, Taraborrelli, Maria, Triggiani, Luca, Franceschini, Davide, Greco, Carlo, Bruni, Alessio, Magrini, Stefano Maria, and Scotti, Vieri
- Published
- 2019
- Full Text
- View/download PDF
6. Lattice Radiation Therapy in clinical practice: A systematic review
- Author
-
Iori, Federico, Cappelli, Anna, Elisa, D'Angelo, Cozzi, Salvatore, Ghersi, Sebastiano, De Felice Francesca, Ciammella, Patrizia, Bruni, Alessio, and Iotti, Cinzia
- Subjects
LRT ,abscopal effect ,bulky ,LRT, lattice radiation therapy ,lattice radiation therapy ,lattice radiotherapy ,OAR, organ at risk ,radiation therapy ,radiotherapy ,SFRT, spatially fractionated radiation therapy ,spatially fractionated radiotherapy ,TCP, tumor control probability ,SFRT ,tumor control probability ,organ at risk ,OAR ,Oncology ,spatially fractionated radiation therapy ,Medicine and Health Sciences ,Radiology, Nuclear Medicine and imaging ,TCP - Abstract
Lattice radiation therapy (LRT) is an innovative type of spatially fractionated radiation therapy. It aims to increase large tumors control probability by administering ablative doses without an increased toxicity. Considering the rising number of positive clinical experiences, the objective of this work is to evaluate LRT safety and efficacy.Reports about LRT clinical experience were identified with a systematic review conducted on four different databases (namely, Medline, Embase, Scopus, and Cochrane Library) through the August 2022. Only LRT clinical reports published in English and with the access to the full manuscript text were considered as eligible. The 2020 update version PRISMA statement was followed.Data extraction was performed from 12 eligible records encompassing 7 case reports, 1 case series, and 4 clinical studies. 81 patients (84 lesions) with a large lesion ranging from 63.2 cc to 3713.5 cc were subjected to exclusive, hybrid, and metabolism guided LRT. Excluding two very severe toxicity with a questionable relation with LRT, available clinical experience seem to confirm LRT safety. When a complete response was not achieved 3-6 months after LRT, a median lesion reduction approximately ≥50 % was registered.This systematic review appear to suggest LRT safety, especially for exclusive LRT. The very low level of evidence and the studies heterogeneity preclude drawing definitive conclusions on LRT efficacy, even though an interesting trend in terms of lesions reduction has been described.
- Published
- 2023
7. Early results of PRO-EPI: PROspective multicenter observational study on elective pelvic nodes irradiation in patients with intermediate/high/very high-risk non-metastatic prostate cancer submitted to radical, adjuvant, or salvage radiotherapy with or without concomitant androgen deprivation therapy
- Author
-
Guerini, Andrea, Noale, Marianna, Mortellaro, Gianluca, Lisi, Roberto, Bruni, Alessio, Santini, Roberto, Muto, Paolo, Ferrera, Giuseppe, Cossali, Gianluca, Morelli, Vittorio, Magrini, Stefano Maria, Spiazzi, Luigi, and Buglione, Michela
- Subjects
IMRT (intensity modulated radiation therapy) ,pelvic nodal irradiation ,IGRT (Image Guided Radiation Therapy) ,ADT ,VMAT (volumetric modulated arc therapy) ,prostate cancer ,radiotherapy - Published
- 2022
8. Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study.
- Author
-
Cozzi, Salvatore, Bruni, Alessio, Ruggieri, Maria Paola, Borghetti, Paolo, Scotti, Vieri, Franceschini, Davide, Fiore, Michele, Taraborrelli, Maria, Salvi, Fabrizio, Galaverni, Marco, Savoldi, Luisa, Braglia, Luca, Botti, Andrea, Finocchi Ghersi, Sebastiano, Niccolò, Giaj-Levra, Lohr, Frank, Iotti, Cinzia, and Ciammella, Patrizia
- Subjects
- *
EVALUATION of medical care , *TREATMENT of lung tumors , *DISEASE progression , *RESEARCH , *SCIENTIFIC observation , *SMALL cell carcinoma , *LUNG tumors , *CHEMORADIOTHERAPY , *TUMOR classification , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *RADIATION doses , *RESEARCH funding , *LONGITUDINAL method - Abstract
Simple Summary: Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and seventy percent of patients already have advanced disease at diagnosis. In advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line chemotherapy, but its use has not yet been standardized. This prospective study was carried out with the intention of evaluating the spread in Italy of the use of thoracic RT in ES-SCLC, with a focus on the pattern of care (RT modalities, volumes and doses) and its effectiveness in terms of disease control and tolerability. From January 2017 to December 2019, sixty-four patients were enrolled. An extensive variability in doses, treatment volume and technique were recorded. Nevertheless, consolidative RT was well-tolerated by all patients and, after treatment, over 66% of patients did not experience in-field progression, and it has been shown to be useful in reducing the risk of thoracic disease progression in patients with advanced stage SCLC, with good response after first-line chemotherapy. (1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a fundamental role in both early and advanced stages. Currently, in advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line chemotherapy, but its use has not yet been standardized. The present prospective study aims to evaluate the pattern of care of consolidative chest RT in patients with advanced stage SCLC, and its effectiveness in terms of disease control and tolerability. (2) Materials and methods: This study was a multicenter prospective observational trial, proposed and conducted within the AIRO lung study group to evaluate the pattern of care of consolidative chest RT after first-line chemotherapy in patients with advanced SCLC. The patient and tumor characteristics, doses, fractionation and volumes of thoracic RT and prophylactic cranial irradiation (PCI), as well as the thoracic and extrathoracic response to the treatment, toxicity and clinical outcomes, were collected and analyzed. (3) Results: From January 2017 to December 2019, sixty-four patients were enrolled. Median follow-up was 33 months. The median age was 68 years (range 42–81); 38 patients (59%) were male and 26 (41%) female. Carboplatin + etoposide for 6 cycles was the most commonly used first-line therapeutic scheme (42%). With regard to consolidative chest RT, 56% of patients (35) received 30 Gy in 10 factions and 16 patients (26%) received 45 Gy in 15 sessions. The modulated intensity technique was used in 84.5% of cases, and post-chemotherapy macroscopic residual disease was the target volume in 87.5% of patients. Forty-four patients (69%) also underwent PCI. At the last follow-up, over 60% of patients did not experience chest disease progression, while 67% showed extrathoracic progression. At the first radiological evaluation after RT, complete response and stable disease were recorded in 6% and 46% of the cases, respectively. Two patients had a long-term complete response to the combined treatment. The brain was the first site of extrathoracic progression in 28%. 1y and 2y OS and PFS were 67%, 19%, 28% and 6%, respectively. Consolidative chest RT was well-tolerated in the majority of patients; it was interrupted in three cases (due to G2 pulmonary toxicity, disease progression and clinical decay, respectively). Only 1 patient developed G3 asthenia. (4) Conclusions: Consolidative chest RT has been shown to be useful in reducing the risk of thoracic disease progression and is absolutely well-tolerated in patients with advanced stage SCLC with good response after first-line chemotherapy. Among the Italian centers that participated in this study, there is still variability in the choice of fractionation and target volumes, although the guidelines contain clear recommendations. The aim of future research should be to clarify the role and modalities of chest RT in the era of immunotherapy in advanced-stage SCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study
- Author
-
Palumbo, Carlotta, Bruni, Alessio, Antonelli, Alessandro, Artibani, Walter, Bassi, Pierfrancesco, Bertoni, Filippo, Borghetti, Paolo, Bracarda, Sergio, Cicchetti, Alessandro, Corvò, Renzo, Gacci, Mauro, Ingrosso, Gianluca, Magrini, Stefano M, Maruzzo, Marco, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Noale, Marianna, Porreca, Angelo, Russi, Elvio, Triggiani, Luca, Tubaro, Andrea, Valdagni, Riccardo, Maggi, Stefania, Conti, Giario N, and Ricardi, Umberto
- Subjects
Male ,Prostatectomy ,Prostatic neoplasms ,Quality of life ,Patient reported outcomes measure ,Radiotherapy ,Watchful waiting ,Urology ,Prostatic Neoplasms ,Androgen Antagonists ,Humans ,Quality of Life ,Percutaneous Coronary Intervention ,Nephrology - Abstract
This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study.Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: nerve sparing radical prostatectomy (NSRP), non-nerve sparing radical prostatectomy (NNSRP), radiotherapy (RT), RT plus androgen deprivation (RT plus ADT) and active surveillance (AS). QoL was measured through the Italian versions of SF-12 and UCLA-PCI questionnaires at diagnosis and at 6-12 and 24-month. The minimal clinically important difference (MCID) was defined as half a standard deviation of the baseline domain.Overall, 1537 patients were included in the study. The decline in urinary function exceeded the MCID at each timepoint only in the NSRP and NNSRP groups (at 24 months -14.7, P0.001 and -19.7, P0.001, respectively). The decline in bowel function exceeded the MCID only in the RT (-9.1, P=0.02) and RT plus ADT groups at 12 months (-10.3, P=0.001); after 24 months, most patients seem to recover their bowel complaints. The decline in sexual function exceeded the MCID at each timepoint in the NNSRP, NSRP and RT plus ADT groups (at 6 months -28.7, P0.001, -37.8, P0.001, -20.4, P0.001, respectively).Although all the treatments were relatively well-tolerated over the 24 month period following PCa diagnosis, each had a different impact on QoL.
- Published
- 2021
10. Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation.
- Author
-
Iori, Federico, Bruni, Alessio, Cozzi, Salvatore, Ciammella, Patrizia, Di Pressa, Francesca, Boldrini, Luca, Greco, Carlo, Nardone, Valerio, Salvestrini, Viola, Desideri, Isacco, De Felice, Francesca, and Iotti, Cinzia
- Subjects
- *
RADIOTHERAPY , *IMMUNOTHERAPY , *TUMOR microenvironment , *ABSCOPAL radiation effects , *COMBINATION drug therapy , *IMMUNE system , *RADIOIMMUNOTHERAPY - Abstract
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients affected by so-called "cold tumors" still represents an open issue. Cold tumors are characterized by an immunosuppressive (so-called cold) tumor microenvironment (TME), which favors host immune system suppression, cancer immune-escape, and a worse response to IT. However, the TME is not a static element, but dynamically mutates and can be changed. Radiotherapy (RT) can modulate a cold microenvironment, rendering it better at tumor killing by priming the quiescent host immune system, with a consequent increase in immunotherapy response. The combination of TME radiomodulation and IT could therefore be a strategy for those patients affected by cold tumors, with limited or no response to IT. Thus, this review aims to provide an easy, rapid, and practical overview of how RT could convert the cold TME and why cold tumor radiomodulation could represent an interesting strategy in combination with IT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report.
- Author
-
Aluisio, Giovanni, Mazzeo, Ercole, Lohr, Frank, Fiocchi, Federica, Bettelli, Stefania, Baldessari, Cinzia, Paterlini, Maurizio, and Bruni, Alessio
- Subjects
MICROSATELLITE repeats ,RADIOTHERAPY ,TUMORS ,IMMUNOHISTOCHEMISTRY ,YEAR - Abstract
Background: Mismatch-repair-deficiency resulting in microsatellite instability (MSI) may confer increased radiosensitivity in locally advanced/metastatic tumors and thus radiotherapy (RT) potentially might have a changing role in treating this subset of patients, alone or in combination with checkpoint inhibitors.Case Presentation: We report a 76 year-old Italian male patient presenting with locally advanced undifferentiated prostate cancer (LAPC), infiltrating bladder and rectum. Molecular analysis revealed high-MSI with an altered expression of MSH2 and MSH6 at immunohistochemistry. Two months after 6 chemotherapy cycles with Docetaxel associated to an LHRH analogue, a computed tomography scan showed stable disease. After palliative RT (30 Gy/10 fractions) directed to the tumor mass with a 3D-conformal setup, a follow-up computed tomography scan at 8 weeks revealed an impressive response that remained stable at computed tomography after 9 months, with sustained biochemical response. To our knowledge, this is the first case of such a sustained response to low dose RT alone in high-MSI LAPC.Conclusions: Routine evaluation of MSI in patients with locally problematic advanced tumors might change treatment strategy and treatment aim in this setting, from a purely palliative approach to a quasi-curative paradigm. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Whole breast external beam radiotherapy in elderly patients affected by left-sided early breast cancer: a dosimetric comparison between two simple free-breathing techniques.
- Author
-
Carosi, Alessandra, Ingrosso, Gianluca, Turturici, Irene, Valeri, Silvio, Barbarino, Rosaria, Di Murro, Luana, Bottero, Marta, Lancia, Andrea, Ponti, Elisabetta, Bruni, Alessio, Bonzano, Elisabetta, Saldi, Simonetta, Andolina, Maria, Aristei, Cynthia, and Santoni, Riccardo
- Subjects
BREAST tumor diagnosis ,BREAST tumors ,BREATHING exercises ,COMPARATIVE studies ,CORONARY arteries ,HEART ,DOSE-response relationship (Radiation) ,PATIENT compliance ,RADIATION doses ,RADIATION dosimetry ,RADIOTHERAPY ,THREE-dimensional imaging ,QUANTITATIVE research ,OLD age - Abstract
Background: Elderly breast cancer patients are frequently affected by significant comorbidities that make sophisticated radiotherapy treatments particularly challenging. Aims: We dosimetrically analyzed two different simple free-breathing external beam radiotherapy (EBRT) techniques for the hypofractionated treatment of the left breast in elderly patients with a low compliance, to compare target coverage, and heart and left anterior descending coronary artery (LADCA) sparing. Methods: We developed radiation plans for 24 elderly patients using 3D conformal (3DCRT) field-in-field tangential technique and intensity-modulated (IMRT) tangential beam technique. Dose-Volume-Histograms (DVHs) were used to provide a quantitative comparison between plans. Results: The median breast volume was 645 cm
3 . IMRT and 3DCRT plans comparison demonstrated no significant differences in terms of organ sparing for the heart. Regarding LADCA, mean dose (10.3 ± 9.5 Gy vs 11.9 ± 9.6 Gy, p = 0.0003), maximum dose (26.1 ± 16.1 Gy vs 29.1 ± 16.1 Gy, p = 0.004) and V17 Gy (21.5% ± 26.9% vs 25.0% ± 27.2%, p = 0.002) significantly decreased using IMRT compared with 3DCRT. IMRT plans showed a better target coverage compared with 3DCRT (0.91 ± 0.05 vs 0.93 ± 0.04, p = 0.05). Discussion: Comparing the two different EBRT techniques, we demonstrated few, although substantial, dosimetric differences in terms of doses to the organs at risk characterized by a statistically significant dose reduction of LADCA in the IMRT plans. Conclusions: Elderly patients with a low compliance to treatment might benefit from 3DCRT with field-in-field tangential arrangement or from a simple IMRT approach. IMRT should be preferred. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Current radiotherapy techniques in NSCLC: challenges and potential solutions.
- Author
-
Giaj-Levra, Niccolò, Borghetti, Paolo, Bruni, Alessio, Ciammella, Patrizia, Cuccia, Francesco, Fozza, Alessandra, Franceschini, Davide, Scotti, Vieri, Vagge, Stefano, and Alongi, Filippo
- Subjects
NON-small-cell lung carcinoma ,RADIOTHERAPY ,STEREOTACTIC radiotherapy - Abstract
Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered: In this review, we provide an overview of technological opportunities and future prospects in NSCLC management.Expert opinion: Stereotactic body radiotherapy (SBRT) is now considered the standard approach in patients ineligible for surgery, while in operable cases, it is still under debate. Additionally, in combination with systemic treatment, SBRT is an innovative option for managing oligometastatic patients and features encouraging initial results in clinical outcomes. To date, in inoperable locally advanced NSCLC, the radical dose prescription has not changed (60 Gy in 30 fractions), despite the median overall survival progressively increasing. These results arise from technological improvements in precisely hitting target treatment volumes and organ at risk sparing, which are associated with better treatment qualities. Finally, for the management of NSCLC, proton and carbon ion therapies and the recent development of MR-Linac are new, intriguing technological approaches under investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO).
- Author
-
Mazzeo, Ercole, Triggiani, Luca, Frassinelli, Luca, Guarneri, Alessia, Bartoncini, Sara, Antognoni, Paolo, Gottardo, Stefania, Greco, Diana, Borghesi, Simona, Nanni, Sara, Bruni, Alessio, Ingrosso, Gianluca, D'Angelillo, Rolando Maria, Detti, Beatrice, Francolini, Giulio, Magli, Alessandro, Guerini, Andrea Emanuele, Arcangeli, Stefano, Spiazzi, Luigi, and Ricardi, Umberto
- Subjects
SURVIVAL ,ACQUISITION of data methodology ,RETROSPECTIVE studies ,CANCER relapse ,MEDICAL records ,RADIATION doses ,RADIOTHERAPY ,PHYSICIAN practice patterns ,RADIATION injuries ,PROSTATE tumors - Abstract
Simple Summary: This is a safety and efficacy analysis from a very large dataset of patients affected by localized prostate cancer having received radiotherapy with or without concomitant androgen deprivation therapy in twelve academic and non-academic Italian Institutions. The aim of this retrospective "real life" study was to provide additional data on clinical presentation, diagnostic workup, radiation therapy management and toxicity as collected within the framework of POP III. Though the usual limitations for a retrospective analysis apply, it nevertheless may expand the current knowledge in this area showing the progress of radiation therapy techniques and clinical outcomes in the period between 2004 and 2011 after a significant period of follow up. Background and purpose: Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. Methods: Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compared with POP II and, when feasible, also with POP I. This report provides data on clinical presentation, diagnostic workup, radiation therapy management, and toxicity as collected within the framework of POP III. Results: More than 50% of POP III patients were classified as low or intermediate risk using D'Amico risk categories as in POP II; 46% were classified as ISUP grade group 1. CT scan, bone scan, and endorectal ultrasound were less frequently prescribed. Dose-escalated radiotherapy (RT), intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), and hypofractionated RT were more frequently offered during the study period. Treatment was commonly well tolerated. Acute toxicity improved compared to the previous series; late toxicity was influenced by prescribed dose and treatment technique. Five-year overall survival, biochemical relapse free survival (BRFS), and disease specific survival were similar to those of the previous series (POP II). BRFS was better in intermediate- and high-risk patients treated with ≥ 76 Gy. Conclusions: This report highlights the improvements in radiotherapy planning and dose delivery among Italian Centers in the 2004–2011 period. Dose-escalated treatments resulted in better biochemical control with a reduction in acute toxicity and higher but acceptable late toxicity, as not yet comprehensively associated with IMRT/IGRT. CTV-PTV margins >8 mm were associated with increased toxicity, again suggesting that IGRT—allowing for tighter margins—would reduce toxicity for dose escalated RT. These conclusions confirm the data obtained from randomized controlled studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study.
- Author
-
Noale, Marianna, Bruni, Alessio, Triggiani, Luca, Buglione, Michela, Bertoni, Filippo, Frassinelli, Luca, Montironi, Rodolfo, Corvò, Renzo, Zagonel, Vittorina, Porreca, Angelo, Bassi, Pierfrancesco, Gacci, Mauro, Conti, Giario Natale, Maggi, Stefania, Magrini, Stefano, and Moreno, Carlos S.
- Subjects
- *
GASTROINTESTINAL system , *CONFIDENCE intervals , *CANCER patients , *QUALITY of life , *DESCRIPTIVE statistics , *DIGESTION , *RADIOTHERAPY , *ODDS ratio , *PROSTATE tumors , *INTESTINES , *SECONDARY analysis , *COMORBIDITY - Abstract
Simple Summary: The analyses presented, based on data from the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study, evaluated patients' reported quality of life outcomes related to bowel function and bother over a 2-year period from the diagnosis. Growth mixture models were considered for patients who underwent radiotherapy, including treatments that were associated or not associated with androgen deprivation therapy. Our data revealed that the proportion of patients that were radiotherapy-treated with persisting significant bowel worsening at the 24 months interval is very limited. The absence of comorbidities and the use of intensity or volumetric radiotherapy techniques with image guidance were found to be related with a better tolerance to radiotherapy in terms of bowel side effects. These findings could be relevant for treatment selection and accurate patient information. Radiotherapy (RT) represents an important therapeutic option for the treatment of localized prostate cancer. The aim of the current study is to examine trajectories in patients' reported quality of life (QoL) aspects related to bowel function and bother, considering data from the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study, analyzed with growth mixture models. Data for patients who underwent RT, either associated or not associated with androgen deprivation therapy, were considered. QoL outcomes were assessed over a 2-year period from the diagnosis, using the Italian version of the University of California Los Angeles-Prostate Cancer Index (Italian-UCLA-PCI). Three trajectories were identified for the bowel function; having three or more comorbidities and the use of 3D-CRT technique for RT were associated with the worst trajectory (OR = 3.80, 95% CI 2.04–7.08; OR = 2.17, 95% CI 1.22–3.87, respectively). Two trajectories were identified for the bowel bother scores; diabetes and the non-Image guided RT method were associated with being in the worst bowel bother trajectory group (OR = 1.69, 95% CI 1.06–2.67; OR = 2.57, 95% CI 1.70–3.86, respectively). The findings from this study suggest that the absence of comorbidities and the use of intensity modulated RT techniques with image guidance are related with a better tolerance to RT in terms of bowel side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. 1215: Oligometastatic Mesothelioma treated with Ablative Radiotherapy (OMAR): multi-institutional database.
- Author
-
Franceschini, Davide, Teriaca, Maria Ausilia, Franzese, Ciro, Ghirardelli, Paolo, Parisi, Elisabetta, Piperno, Gaia, Sepulcri, Matteo, Krengli, Marco, Jereczec-Fossa, Barbara, Romeo, Antonino, Vavassori, Vittorio, Bruni, Alessio, Andratschke, Nicolaus, Guckenberger, Matthias, Ceresoli, Giovanni Luca, and Scorsetti, Marta
- Subjects
- *
DATABASES , *MESOTHELIOMA , *RADIOTHERAPY - Published
- 2024
- Full Text
- View/download PDF
17. COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
- Author
-
Jereczek-Fossa, Barbara Alicja, Pepa, Matteo, Marvaso, Giulia, Bruni, Alessio, Buglione di Monale e Bastia, Michela, Catalano, Gianpiero, Filippi, Andrea Riccardo, Franco, Pierfrancesco, Gambacorta, Maria Antonietta, Genovesi, Domenico, Iatì, Giuseppe, Magli, Alessandro, Marafioti, Luigi, Meattini, Icro, Merlotti, Anna, Mignogna, Marcello, Musio, Daniela, Pacelli, Roberto, Pergolizzi, Stefano, and Tombolini, Vincenzo
- Subjects
- *
COVID-19 pandemic , *CANCER radiotherapy , *CANCER patient care , *ONCOLOGY , *RADIOTHERAPY - Abstract
Italy experienced one of the world's deadliest COVID-19 outbreaks and healthcare systems had to instantly reorganise activity. The Italian Radiation Oncology Departments adapted numerous solutions to minimize the disruptions. Information technologies, treatment prioritization and implementation of hypofractionation and protection procedures allowed balancing between cancer patient care and patient/healthcare workers safety. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
- Author
-
De Bleser, Elise, Jereczek-Fossa, Barbara Alicja, Pasquier, David, Zilli, Thomas, Van As, Nicholas, Siva, Shankar, Fodor, Andrei, Dirix, Piet, Gomez-Iturriaga, Alfonso, Trippa, Fabio, Detti, Beatrice, Ingrosso, Gianluca, Triggiani, Luca, Bruni, Alessio, Alongi, Filippo, Reynders, Dries, De Meerleer, Gert, Surgo, Alessia, Loukili, Kaoutar, and Miralbell, Raymond
- Subjects
- *
STEREOTACTIC radiotherapy , *CASTRATION-resistant prostate cancer , *PROSTATE cancer , *RADIOTHERAPY , *POSITRON emission tomography - Abstract
Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking. To compare outcome and toxicity between both treatments. Primary endpoint was metastasis-free survival, adjusted for selected variables (aMFS). This was a multi-institutional, retrospective analysis of 506 (SBRT: 309, ENRT: 197) patients with hormone-sensitive nodal oligorecurrent PC (five or fewer lymph nodes (LNs; N1/M1a), treated between 2004 and 2017. Median follow-up was 36 mo (interquartile range 23–56). SBRT was defined as a minimum of 5 Gy per fraction to each lesion with a maximum of 10 fractions. ENRT was defined as a minimum dose of 45 Gy in up to 25 fractions to the elective nodes, with or without a simultaneous boost to the suspicious node(s). The choice of radiotherapy (RT) was at the discretion of the treating physician, with treatments being unbalanced over the centers. In total, 506 patients from 15 different treatment centers were included. Primary treatment was radical prostatectomy, RT, or their combination. Nodal recurrences were detected by positron emission tomography/computer tomography (97%) or conventional imaging (3%). Descriptive statistics was used to summarize patient characteristics. ENRT was associated with fewer nodal recurrences compared with SBRT (p < 0.001). In a multivariable analysis, patients with one LN at recurrence had longer aMFS after ENRT (hazard ratio: 0.50, 95% confidence interval 0.30–0.85, p = 0.009). Late toxicity was higher after ENRT compared with that after SBRT (16% vs. 5%, p < 0.01). Limitations include higher use of hormone therapy in the ENRT cohort and nonstandardized follow-up. ENRT reduces the number of nodal recurrences as compared with SBRT, however at higher toxicity. Our findings hypothesize that ENRT should be preferred to SBRT in the treatment of nodal oligorecurrences. This hypothesis needs to be evaluated in a randomized trial. This study investigated the difference between stereotactic and elective nodal radiotherapy in treating limited nodal metastatic prostate cancer. Nodal relapse was less frequent following elective nodal radiotherapy than following stereotactic body radiotherapy, and thus elective nodal radiotherapy might be the preferred treatment. In treating nodal oligorecurrent prostate cancer, elective nodal radiotherapy reduces nodal relapse compared with stereotactic body radiotherapy. However, elective nodal radiotherapy was associated with higher toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Evaluation of the effectiveness of novel single-intervention adaptive radiotherapy strategies based on daily dose accumulation.
- Author
-
Ciarmatori, Alberto, Maffei, Nicola, Mistretta, Grazia Maria, Ceroni, Paola, Bernabei, Annalisa, Meduri, Bruno, D'Angelo, Elisa, Bruni, Alessio, Giacobazzi, Patrizia, Lohr, Frank, and Guidi, Gabriele
- Subjects
- *
DEFORMATION of surfaces , *COMPUTED tomography , *RADIOTHERAPY , *VECTOR fields , *IMAGE registration , *PAROTID glands - Abstract
Parotid gland (PG) shrinkage and neck volume reduction during radiotherapy of head and neck (H&N) cancer patients is a clinical issue that has prompted interest in adaptive radiotherapy (ART). This study focuses on the difference between planned dose and delivered dose and the possible effects of an efficient replanning strategy during the course of treatment. Six patients with H&N cancer treated by tomotherapy were retrospectively enrolled. Thirty daily dose distributions (D MVCT) were calculated on pretreatment megavoltage computed tomography (MVCT) scans. Deformable Image Registration which matched daily MVCT with treatment planning kilovoltage computed tomography was performed. Using the resulting deformation vector field, all daily D MVCT were deformed to the planning kilovoltage computed tomography and resulting doses were accumulated voxel per voxel. Cumulative D MVCT was compared to planned dose distribution performing γ-analysis (2 mm, 2% of 2.2 Gy). Two single-intervention ART strategies were executed on the 18th fraction whose previous data had suggested to be a suitable timepoint for a single replanning intervention: (1) replanning on the original target and deformed organ at risks (OARs) (a "safer" approach regarding tumor coverage) and (2) replanning on both deformed target and deformed OARs. D MVCT showed differences between planned and delivered doses (3D-γ 2mm/2%-passing rate = 85 ± 1%, p < 0.001). Voxel by voxel dose accumulation showed an increase in average dose of warped PG of 3.0 Gy ± 3.3 Gy. With ART the average dose of warped PG decreased by 3.2 Gy ± 1.7 Gy in comparison to delivered dose without replanning when both target and OARs were deformed. Average dose of warped PG decreased by 2.0 Gy ± 1.4 Gy when only OARs were deformed. Anatomical variations lead to increased doses to PGs. Efficient single-intervention ART-strategies with replanning on the 18th MVCT result a reduced PG dose. A strategy with deformation of both target and OAR resulted in the lowest PG dose, while formally maintaining PTV coverage. Deformation of only OAR nevertheless reduces PG dose and has less uncertainties regarding PTV coverage. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Post-operative radiotherapy in N2 non-small cell lung cancer: A retrospective analysis of 175 patients
- Author
-
Scotti, Vieri, Meattini, Icro, Saieva, Calogero, Agresti, Benedetta, de Luca Cardillo, Carla, Bastiani, Paolo, Livi, Lorenzo, Mangoni, Monica, Cataldo, Vanessa Di, Marrazzo, Livia, Rampini, Andrea, Cipressi, Samantha, Bruni, Alessio, Santini, Paolo, and Biti, Giampaolo
- Subjects
- *
CANCER radiotherapy , *CHEST X rays , *SMALL cell lung cancer , *POSTOPERATIVE care , *RETROSPECTIVE studies , *CANCER relapse , *FOLLOW-up studies (Medicine) , *PATIENTS - Abstract
Abstract: Background and purpose: Post-operative radiotherapy (PORT) in radically resected non-small cell lung cancer (NSCLC) has the aim to reduce loco regional recurrence and to improve overall survival. PORT has been evaluated in several trials but indication to post-operative treatment in N2 patients is still debated. Material and methods: We retrospectively analyzed 175 patients treated at University of Florence between 1988 and 2004 with completely resected NSCLC stages IIIA–IIIB, N2 disease. Surgery consisted in a lobectomy in 58.9% and in a bi-lobectomy or in a pneumonectomy in 41.1% of patients. One hundred and nineteen patients underwent PORT and 56 patients did not receive PORT (no-PORT). Results: At a median follow-up of 27.6months (range 4–233months), we found a significant reduction in local recurrence (LR) in PORT group (log-rank test p =0.015; HR: 0.45; 95%CI: 0.24–0.87). No statistical difference were found in terms of overall survival (OS) (log-rank test p =0.92). Concerning other prognostic factors, male sex emerged as statistically significant (HR:4.33;1.04–18.02) on local progression free survival (LPFS) at univariate analysis. Acute and long-term toxicity was mild. Conclusion: Our retrospective analysis showed that PORT may improve local disease control in N2 NSCLC patients with an acceptable treatment-related toxicity. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
21. Management of Stage II testicular seminoma over a period of 40 years
- Author
-
Detti, Beatrice, Livi, Lorenzo, Scoccianti, Silvia, Gacci, Mauro, Lapini, Alberto, Cai, Tommaso, Meattini, Icro, Mileo, Anna Maria, Iannalfi, Alberto, Bruni, Alessio, and Biti, Giampaolo
- Subjects
- *
TESTICULAR cancer , *TUMOR classification , *RETROSPECTIVE studies , *CANCER diagnosis , *CANCER radiotherapy , *CANCER chemotherapy , *HEALTH outcome assessment , *FOLLOW-up studies (Medicine) ,TESTIS surgery - Abstract
Abstract: Objectives: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy. Materials and methods: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19–71). Median follow-up was 21 years (range: 1.2–42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96% for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94%, 72.5%, and 75%, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7%) patients during the follow-up. Conclusions: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
22. Radiotherapy Timing in 4,820 Patients With Breast Cancer: University of Florence Experience
- Author
-
Livi, Lorenzo, Borghesi, Simona, Saieva, Calogero, Meattini, Icro, Rampini, Andrea, Petrucci, Alessia, Detti, Beatrice, Bruni, Alessio, Paiar, Fabiola, Mangoni, Monica, Marrazzo, Livia, Agresti, Benedetta, Cataliotti, Luigi, Bianchi, Simonetta, and Biti, Giampaolo
- Subjects
- *
CANCER radiotherapy , *CONTROLLED release drugs , *BREAST cancer patients , *BREAST cancer surgery , *BREAST cancer prognosis , *MULTIVARIATE analysis - Abstract
Purpose: To analyze the relationship between a delay in radiotherapy (RT) after breast-conserving surgery and ipsilateral breast recurrence (BR). Methods and Materials: We included in our analysis 4,820 breast cancer patients who had undergone postoperative RT at the University of Florence. The patients were categorized into four groups according to the interval between surgery and RT (T1, <60 days; T2, 61–120 days; T3, 121–180 days; and T4, >180 days). Results: On multivariate analysis, the timing of RT did not reach statistical significance in patients who received only postoperative RT (n = 1,935) or RT and hormonal therapy (HT) (n = 1,684) or RT, chemotherapy (CHT), and HT (n = 529). In the postoperative RT-only group, age at presentation, surgical margin status, and a boost to the tumor bed were independent prognostic factors for BR. In the RT plus HT group, age at presentation and boost emerged as independent prognostic factors for BR (p = 0.006 and p = 0.049, respectively). Finally, in the RT, CHT, and HT group, only multifocality was an independent BR predictor (p = 0.01). Only in the group of patients treated with RT and CHT (n = 672) did multivariate analysis with stepwise selection show RT timing as an independent prognostic factor (hazard ratio, 1.59; 95% confidence interval, 1.01–2.52; p = 0.045). Analyzing this group of patients, we found that most patients included had worse prognostic factors and had received CHT consisting of cyclophosphamide, methotrexate, and 5-fluorouracil before undergoing RT. Conclusion: The results of our study have shown that the timing of RT itself does not affect local recurrence, which is mainly related to prognostic factors. Thus, the “waiting list” should be thought of as a “programming list,” with patients scheduled for RT according to their prognostic factors. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.